Vitiligo Market 2027

DelveInsight's 'Vitiligo - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Vitiligo in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Vitiligo from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan


Study Period: 2016-2027

Vitiligo - Disease Understanding and Treatment Algorithm

The DelveInsight Vitiligo market report gives the thorough understanding of the Vitiligo by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Vitiligo in the US, Europe, and Japan.


Vitiligo Epidemiology

The Vitiligo epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Prevalent population, Sex specific cases, Diagnosed Cases, Type Specific Diagnosed cases (segmental, non-segmental and unclassified) and Age Specific cases] scenario of Vitiligo in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the total prevalent population of Vitiligo was found to be 61, 36,840, in the year 2016.


Vitiligo Drug Chapters

This segment of the Vitiligo report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market of Vitiligo is mainly accounted by the off-label use of Corticosteroids and Calcineurin inhibitors, both as monotherapy as well as combination therapies. Phototherapy is also used in combination with these therapies. Topical Corticosteroids and calcineurin inhibitors constitute the first line of treatment for Vitiligo. Corticosteroids have their own shortcomings, therefore when used in combination with calcineurin inhibitors, they are found to be very much effective in the management of Vitiligo, by resulting in increased repigmentation. Detailed chapters of upcoming therapies such as INCB018424 (Incyte Corporation), and Scenesse (Clinuvel Pharmaceutical) which are expected to get launch during the forecast period have also been covered in the report.


Vitiligo Market Outlook

The Vitiligo market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the total market size of Vitiligo in 7MM was found to be USD 878.5 million in 2016.


Vitiligo Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Vitiligo Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Vitiligo Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition


Vitiligo Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Vitiligo market
  • Organize sales and marketing efforts by identifying the best opportunities for Vitiligo market
  • To understand the future market competition in the Vitiligo market.

1. Key Insights

2. Vitiligo Market Overview at a Glance

2.1. Market Share (%) Distribution of Vitiligo in 2016

2.2. Market Share (%) Distribution of Vitiligo in 2027

3. Disease Background and Overview: Vitiligo

3.1. Introduction

3.2. Types of Vitiligo

3.3. Causes of Vitiligo

3.4. Symptoms of Vitiligo

3.5. Pathophysiology

3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Population and Forecast Parameters

4.3. Prevalent Population of Vitiligo in 7MM

5. Country Wise-Epidemiology of Vitiligo

6. United States

6.1. Assumptions and Rationale

6.2. Prevalent Population of Vitiligo in the United States

6.3. Sex Specific Prevalent Population of Vitiligo in the United States

6.4. Diagnosed Cases of Vitiligo in the United States

6.5. Type Specific Diagnosed Prevalent cases of Vitiligo in the United States

6.6. Age Specific Prevalent cases of Vitiligo in the United States

7. EU-5

7.1. Assumptions and Rationale

8. Germany

8.1. Prevalent Population of Vitiligo in Germany

8.2. Sex Specific Prevalent Population of Vitiligo in Germany

8.3. Diagnosed Cases of Vitiligo in Germany

8.4. Type Specific Diagnosed Prevalent cases of Vitiligo in Germany

8.5. Age Specific Prevalent cases of Vitiligo in Germany

9. France

9.1. Prevalent Population of Vitiligo in France

9.2. Sex Specific Prevalent Population of Vitiligo in France

9.3. Diagnosed Cases of Vitiligo in France

9.4. Type Specific Diagnosed Prevalent cases of Vitiligo in France

9.5. Age Specific Prevalent cases of Vitiligo in France

10. Italy

10.1. Prevalent Population of Vitiligo in Italy

10.2. Sex Specific Prevalent Population of Vitiligo in Italy

10.3. Diagnosed Cases of Vitiligo in Italy

10.4. Type Specific Diagnosed Prevalent cases of Vitiligo in Italy

10.5. Age Specific Prevalent cases of Vitiligo in Italy

11. Spain

11.1. Prevalent Population of Vitiligo in Spain

11.2. Sex Specific Prevalent Population of Vitiligo in Spain

11.3. Diagnosed Cases of Vitiligo in Spain

11.4. Type Specific Diagnosed Prevalent cases of Vitiligo in Spain

11.5. Age Specific Prevalent cases of Vitiligo in Spain

12. United Kingdom

12.1. Prevalent Population of Vitiligo in the United Kingdom

12.2. Sex Specific Prevalent Population of Vitiligo in the United Kingdom

12.3. Diagnosed Cases of Vitiligo in the UK

12.4. Type Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom

12.5. Age Specific Prevalent cases of Vitiligo in the UK

13. Japan

13.1. Assumptions and Rationale

13.2. Prevalent Population of Vitiligo in Japan

13.3. Sex Specific Prevalent Population of Vitiligo in Japan

13.4. Diagnosed Cases of Vitiligo in Japan

13.5. Type Specific Diagnosed Prevalent cases of Vitiligo in Japan

13.6. Age Specific Prevalent cases of Vitiligo in Japan

14. Treatment Algorithm

14.1. Treatment Guidelines

14.1.1. American Association of Dermatology (AAD)

14.1.2. The European Dermatology Forum Consensus: Management guidelines for Vitiligo

14.1.3. Vitiligo Japanese Task Force (VJTF); Japanese Dermatological Association: Treatment Guidelines

15. Unmet Needs

16. Emerging Therapies

16.1. INCB018424: Incyte Corporation

16.1.1. Product Description

16.1.2. Other development activities

16.1.3. Clinical Development

16.1.4. Safety and Efficacy

16.1.5. Product Profile

16.2. SCENESSE (afamelanotide): Clinuvel Pharmaceutical

16.2.1. Product Description

16.2.2. Clinical Development

16.2.3. Safety and Efficacy

16.2.4. Product Profile

17. Other Promising Candidates

17.1. ATI-50002: Aclaris Therapeutics

17.1.1. Product Description

17.1.2. Other Development Activities

17.1.3. Clinical Development

17.1.4. Safety and Efficacy

17.1.5. Product Profile

17.2. Apremilast: Celgene

17.2.1. Product Description

17.2.2. Clinical Development

17.2.3. Product Profile

18. Vitiligo: 7 Major Market Analysis

18.1. Key Findings

18.2. Total Market Size of Vitiligo in 7MM

18.3. 7 MM Size of Vitiligo by Therapies

19. Market Outlook by Country

19.1. The United States: Market Outlook

19.2. United States Market Size

19.2.1. Total Market size of Vitiligo

19.2.2. Vitiligo Market Size by Therapies

19.3. EU-5 Countries: Market Outlook

19.4. Germany Market Size

19.4.1. Total Market size of Vitiligo

19.4.2. Vitiligo Market Size by Therapies

19.5. France Market Size

19.5.1. Total Market size of Vitiligo

19.5.2. Vitiligo Market Size by Therapies

19.6. Italy Market Size

19.6.1. Total Market size of Vitiligo

19.6.2. Vitiligo Market Size by Therapies

19.7. Spain Market Size

19.7.1. Total Market size of Vitiligo

19.7.2. Vitiligo Market Size Therapies

19.8. The United Kingdom Market Size

19.8.1. Total Market size of Vitiligo

19.8.2. Vitiligo Market Size by Therapies

19.9. Japan: Market Outlook

19.9.1. Japan: Market Size

19.9.2. Total Market size of Vitiligo

19.9.3. Vitiligo Market Size by Therapies

20. Market Drivers

21. Market Barriers

22. Appendix

23. Report Methodology

23.1. Sources Used

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

Table 1: Total Prevalent Population of Vitiligo in 7MM (2016-2027)

Table 2: Prevalent Population of Vitiligo in the United States (2016-2027)

Table 3: Sex Specific Prevalent Population of Vitiligo in the United States (2016-2027)

Table 4: Diagnosed cases of Vitiligo in the United States (2016-2027)

Table 5: Type Specific Diagnosed Prevalent cases of Vitiligo in the United States (2016-2027)

Table 6: Age Specific Prevalent cases of Vitiligo in the United States (2018)

Table 7: Prevalent Population of Vitiligo in Germany (2016-2027)

Table 8: Sex Specific Prevalent Population of Vitiligo in Germany (2016-2027)

Table 9: Diagnosed cases of Vitiligo in Germany (2016-2027)

Table 10: Type Specific Diagnosed Prevalent cases of Vitiligo in Germany (2016-2027)

Table 11: Age Specific Prevalent cases of Vitiligo in Germany (2018)

Table 12: Prevalent Population of Vitiligo in France (2016-2027)

Table 13: Sex Specific Prevalent Population of Vitiligo in France (2016-2027)

Table 14: Diagnosed cases of Vitiligo in France (2016-2027)

Table 15: Type Specific Diagnosed Prevalent cases of Vitiligo in France (2016-2027)

Table 16: Age Specific Prevalent cases of Vitiligo in France (2018)

Table 17: Prevalent Population of Vitiligo in Italy (2016-2027)

Table 18: Sex Specific Prevalent Population of Vitiligo in Italy (2016-2027)

Table 19: Diagnosed cases of Vitiligo in Italy (2016-2027)

Table 20: Type Specific Diagnosed Prevalent cases of Vitiligo in Italy (2016-2027)

Table 21: Age Specific Prevalent cases of Vitiligo in Italy (2018)

Table 22: Prevalent Population of Vitiligo in Spain (2016-2027)

Table 23: Sex Specific Prevalent Population of Vitiligo in Spain (2016-2027)

Table 24: Diagnosed cases of Vitiligo in Spain (2016-2027)

Table 25: Type Specific Diagnosed Prevalent cases of Vitiligo in Spain (2016-2027)

Table 26: Age Specific Prevalent cases of Vitiligo in Spain (2018)

Table 27: Prevalent Population of Vitiligo in the United Kingdom (2016-2027)

Table 28: Sex Specific Prevalent Population of Vitiligo in the United Kingdom (2016-2027)

Table 29: Diagnosed cases of Vitiligo in the UK (2016-2027)

Table 30: Type Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2016-2027)

Table 31: Age Specific Prevalent cases of Vitiligo in the UK (2018)

Table 32: Prevalent Population of Vitiligo in Japan (2016-2027)

Table 33: Sex Specific Prevalent Population of Vitiligo in the Japan (2016-2027)

Table 34: Diagnosed cases of Vitiligo in Japan (2016-2027)

Table 35: Type Specific Diagnosed Prevalent cases of Vitiligo in Japan (2016-2027)

Table 36: Age Specific Prevalent cases of Vitiligo in Japan (2018)

Table 37: INCB018424, Clinical Trial Description, 2018

Table 38: SCENESSE, Clinical Trial Description, 2018

Table 39: ATI-50002, Clinical Trial Description, 2018

Table 40: Apremilast, Clinical Trial Description, 2018

Table 41: 7 Major Market Size of Vitiligo in USD Million (2016-2027)

Table 42: 7 Major Market Vitiligo Market Size by Therapies in USD Million (2016-2027)

Table 43: The US Market Vitiligo in USD Million (2016-2027)

Table 44: The US Vitiligo Market Size by Therapies in USD Million (2016-2027)

Table 45: Germany Market Vitiligo in USD Million (2016-2027)

Table 46: Germany Vitiligo Market Size by Therapies in USD Million (2016-2027)

Table 47: France Market Vitiligo in USD Million (2016-2027)

Table 48: France Vitiligo Market Size by Therapies in USD Million (2016-2027)

Table 49: Italy Market Vitiligo in USD Million (2016-2027)

Table 50: Italy Vitiligo Market Size by Therapies in USD Million (2016-2027)

Table 51: The Spain Market Vitiligo in USD Million (2016-2027)

Table 52: Spain Vitiligo Market Size by Therapies in USD Million (2016-2027)

Table 53: The UK Market Vitiligo in USD Million (2016-2027)

Table 54: The UK Vitiligo Market Size by Therapies in USD Million (2016-2027)

Table 55: Japan Market Vitiligo in USD Million (2016-2027)

Table 56:Japan Vitiligo Market Size by Therapies in USD Million (2016-2027)

Figure 1: Types of Vitiligo

Figure 2: Type of Non-segmental Vitiligo

Figure 3: Cellular and Humoral immune mechanisms of Vitiligo

Figure 4: Pathogenesis of Vitiligo

Figure 5: Total Prevalent Population of Vitiligo in 7 MM (2016-2027)

Figure 6: Prevalent Population of Vitiligo in the United States (2016-2027)

Figure 7: Sex Specific Prevalent Population of Vitiligo in the United States (2016-2027)

Figure 8: Diagnosed cases of Vitiligo in the United States (2016-2027)

Figure 9: Type Specific Diagnosed Prevalent cases of Vitiligo in the United States (2016-2027)

Figure 10: Age Specific Prevalent cases of Vitiligo in the United States (2018)

Figure 11: Prevalent Population of Vitiligo in Germany (2016-2027)

Figure 12: Sex Specific Prevalent Population of Vitiligo in Germany (2016-2027)

Figure 13: Diagnosed cases of Vitiligo in the Germany (2016-2027)

Figure 14: Type Specific Diagnosed Prevalent cases of Vitiligo in Germany (2016-2027)

Figure 15: Age Specific Prevalent cases of Vitiligo in Germany (2018)

Figure 16: Prevalent Population of Vitiligo in France (2016-2027)

Figure 17: Sex Specific Prevalent Population of Vitiligo in France (2016-2027)

Figure 18: Diagnosed cases of Vitiligo in France (2016-2027)

Figure 19: Type Specific Diagnosed Prevalent cases of Vitiligo in France (2016-2027)

Figure 20: Age Specific Prevalent cases of Vitiligo in France (2018)

Figure 21: Prevalent Population of Vitiligo in Italy (2016-2027)

Figure 22: Sex Specific Prevalent Population of Vitiligo in Italy (2016-2027)

Figure 23: Diagnosed cases of Vitiligo in Italy (2016-2027)

Figure 24: Type Specific Diagnosed Prevalent cases of Vitiligo in Italy (2016-2027)

Figure 25: Age Specific Prevalent cases of Vitiligo in Italy (2018)

Figure 26: Prevalent Population of Vitiligo in Spain (2016-2027)

Figure 27: Sex Specific Prevalent Population of Vitiligo in Spain (2016-2027)

Figure 28: Diagnosed cases of Vitiligo in Spain (2016-2027)

Figure 29: Type Specific Diagnosed Prevalent cases of Vitiligo in Spain (2016-2027)

Figure 30: Age Specific Prevalent cases of Vitiligo in Spain (2018)

Figure 31: Prevalent Population of Vitiligo in the United Kingdom (2016-2027)

Figure 32: Sex Specific Prevalent Population of Vitiligo in the United Kingdom (2016-2027)

Figure 33: Diagnosed cases of Vitiligo in the United Kingdom (2016-2027)

Figure 34: Type Specific Diagnosed Prevalent cases of Vitiligo in the United Kingdom (2016-2027)

Figure 35: Age Specific Prevalent cases of Vitiligo in the United Kingdom (2018)

Figure 36: Prevalent Population of Vitiligo in Japan (2016-2027)

Figure 37: Sex Specific Prevalent Population of Vitiligo in Japan (2016-2027)

Figure 38: Diagnosed cases of Vitiligo in Japan (2016-2027)

Figure 39: Type Specific Diagnosed Prevalent cases of Vitiligo in Japan (2016-2027)

Figure 40: Age Specific Prevalent cases of Vitiligo in Japan (2018)

Figure 41: Treatment algorithm for Vitiligo

Figure 42: Unmet Needs for Vitiligo

Figure 43: 7 Major Market Size of Vitiligo in USD Million (2016-2027)

Figure 44: 7 Major Market Size of Vitiligo by Therapies in USD Million (2016-2027)

Figure 45: Market Size of Vitiligo in the United States, USD Millions (2016-2027)

Figure 46: The U.S. Vitiligo Market Size by Therapies in USD Million (2016-2027)

Figure 47: Market Size of Vitiligo in the Germany, USD Millions (2016-2027)

Figure 48: Germany Vitiligo Market Size by Therapies in USD Million (2016-2027)

Figure 49: Market Size of Vitiligo in France, USD Millions (2016-2027)

Figure 50: France Vitiligo Market Size by Therapies in USD Million (2016-2027)

Figure 51: Market Size of Vitiligo in Italy, USD Millions (2016-2027)

Figure 52: Italy Vitiligo Market Size by Therapies in USD Million (2016-2027)

Figure 53: Market Size of Vitiligo in Spain, USD Millions (2016-2027)

Figure 54: Spain Vitiligo Market Size by Therapies in USD Million (2016-2027)

Figure 55: Market Size of Vitiligo in UK, USD Millions (2016-2027)

Figure 56: The UK Vitiligo Market Size by Therapies in USD Million (2016-2027)

Figure 57: Market Size of Vitiligo in Japan, USD Millions (2016-2027)

Figure 58: Japan Vitiligo Market Size by Therapies in USD Million (2016-2027)

Figure 59: Market Drivers of Vitiligo

Figure 60:Market Barriers of Vitiligo

  • Tags:
  • Vitiligo market
  • Vitiligo market research
  • Vitiligo market insight
  • Vitiligo market trends
  • Vitiligo market forecast
  • Vitiligo market share
  • Vitiligo pipeline drugs
  • Vitiligo treatment algorithm
  • Vitiligo drugs
  • Vitiligo sales forecasting
  • Vitiligo market size
  • Vitiligo disease
  • Vitiligo epidemiology
  • Vitiligo
  • Vitiligo Companies
  • Vitiligo Pipeline

Forward to Friend

Need A Quote